Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MERTK | Q12866 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 4/20 | 0.46 |
| ▸ | GSR | P00390 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29677457 | 1.00 | MAPT (0.47) | MAPTMERTKTXNRD1GSRTDP1 | |
| Ammonia Solution, Strong SCHEMBL28178631 | 0.98 | MAPT (0.46) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL671296 | 0.83 | TDP1 (0.45) | MAPTTDP1POLBL3MBTL1TSHR | |
| SCHEMBL29391396 | 0.83 | TDP1 (0.45) | MAPTTDP1POLBL3MBTL1TSHR | |
| SCHEMBL29364858 | 0.79 | MAPT (0.50) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL56616 | 0.79 | MAPT (0.50) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL30271385 | 0.78 | MAPT (0.53) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL17434625 | 0.78 | MAPT (0.49) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL8710611 | 0.78 | MAPT (0.53) | MAPTMERTKTXNRD1GSRTDP1 | |
| SCHEMBL6990761 | 0.78 | MAPT (0.49) | MAPTMERTKTXNRD1GSRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1073 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510400-A | Preparation method of 6-bromo-2-chloro-3-nitropyridine | 山西永津集团有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-105541705-B | A kind of synthetic method of flupirtine maleate compound | 山东罗欣药业集团恒欣药业有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-106397313-A | High efficient synthesis method of flupirtine maleate | 安徽省润生医药股份有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-106397314-A | Rivastigmine hydrogen tartrate preparation method and application thereof | 安徽省润生医药股份有限公司 | 2017-02-15 | — | — | CN | claimed |
| CN-103936766-B | A kind of 5(4H)-pyridone the synthetic method of furazan oxide | 盐城师范学院 | 2016-09-14 | — | — | CN | claimed |
| CN-104086481-B | A kind of synthetic method of flupirtine maleate | SICHUAN XINSIDUN PHARMACEUTICAL CO., LTD. (CN) | 2016-05-11 | — | — | CN | claimed |
| CN-105541705-A | Synthesis method for flupirtine maleate compound | SHANDONG LUOXIN PHARMACEUTICAL GROUP CO LTD | 2016-05-04 | — | — | CN | claimed |
| CN-103333103-B | Method for preparing flupirtine maleate by one-pot method | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO LTD | 2015-07-22 | — | — | CN | claimed |
| CN-104086481-A | Synthesis method of flupirtine maleate | SICHUAN XINSIDUN PHARMACEUTICAL CO LTD | 2014-10-08 | — | — | CN | claimed |
| CN-103936766-A | Synthesis method of 4H-pyridofuroxan-5-one | YANCHENG TEACHERS COLLEGE | 2014-07-23 | — | — | CN | claimed |
| EP-1017384-B1 | AZABENZIMIDAZOLE-BASED COMPOUNDS FOR MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION | ZENTARIS GMBH (DE) | 2004-11-10 | — | — | EP | claimed |
| CN-1169527-C | Method for in vitro regulation of serine/threonine protein kinase function by using 5-azaquinoxaline compound | — | 2004-10-06 | — | — | CN | claimed |
| CN-1167420-C | Azabenzimidazoles for modulating serine/threonine protein kinase function | — | 2004-09-22 | — | — | CN | claimed |
| US-20030181480-A1 | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds | ZENTARIS AG | 2003-09-25 | — | — | US | claimed |
| CN-1278172-A | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function | ASTA MEDIA AG (DE) | 2000-12-27 | — | — | CN | claimed |
| CN-1274284-A | Methods of modulating serine/threnoine protein kinase function with 5-azaquinoxaline-based compounds | ASTA MEDICA AG (DE) | 2000-11-22 | — | — | CN | claimed |
| EP-1028729-A2 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH 5-AZAQUINOXALINE-BASED COMPOUNDS | ASTA Medica Aktiengesellschaft (DE) | 2000-08-23 | — | — | EP | claimed |
| EP-1017384-A1 | AZABENZIMIDAZOLE-BASED COMPOUNDS FOR MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION | ASTA Medica Aktiengesellschaft (DE) | 2000-07-12 | — | — | EP | claimed |
| WO-1999017759-A2 | METHODS OF MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION WITH 5-AZAQUINOXALINE-BASED COMPOUNDS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-04-15 | — | — | WO | claimed |
| WO-1999016438-A1 | AZABENZIMIDAZOLE-BASED COMPOUNDS FOR MODULATING SERINE/THREONINE PROTEIN KINASE FUNCTION | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 1999-04-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181480-A1 | Methods of modulating serine/threonine protein kinase function with azabenzimidazole-based compounds | MTOR, BRAF, MKNK1 | MAPT 1975/4885MERTK 764/4885TXNRD1 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.